Thyrocare opens new state-of-the-art genomics lab In Navi Mumbai

Thyrocare Technologies, a leading healthcare diagnostics company in India to have achieved 100% NABL accreditation across all its laboratories, has announced the launch of its state-of-the-art genomics laboratory in Navi Mumbai.

With this launch, Thyrocare is expanding its portfolio with a new range of speciality tests in genomics, powered by a state-of-the-art facility equipped with advanced next-generation sequencing technologies and supported by robust bioinformatics and data interpretation capabilities.

Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence. This is further supported by a newly onboarded specialised on-ground team, ensuring seamless delivery and accelerating adoption of these advanced testing capabilities.

Sharing his thoughts on the same, Rahul Guha, MD & CEO, Thyrocare and API Holdings said, 'At Thyrocare, we have consistently focused on building a diagnostics platform that is scalable, standardised, and accessible. The launch of our genomics laboratory marks a significant step forward in this journey, as we expand into advanced, high-impact areas of testing. As healthcare continues to move towards predictive and preventive care, genomics will play a critical role in enabling early insights and better clinical decision-making. With this expansion, we aim to make advanced genomics testing more accessible and affordable while continuing to build on our proven model of high-throughput, quality-driven diagnostics.” 

The launch of the new genomics lab by Thyrocare in Mumbai highlights a pivotal shift towards preventive and data-driven healthcare in India. By the integration of advanced genetic insights with its strong diagnostic network, the company aims to support a more data-driven, preventive and personalised approach to healthcare in India.